biologic

Trumenba

Meningococcal Group B Vaccine

Loss of exclusivityOctober 2026FDA regulatory exclusivity expiry
CompanyWyethView the full company profile on CliffBio

Drug detail

Brand nameTrumenba
Active ingredientMeningococcal Group B Vaccine
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalOctober 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Trumenba patent cliff — loss of exclusivity October 2026 | CliffBio